Biomarker ID | 1895 |
PMID | 30611450 |
Year | 2019 |
Biomarker | HDAC9 |
Biomarker Basis | Expression Based |
Biomolecule | DNA (Copy Number variations) |
Source | Tissue |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: NFAT involvement in hypertrophy of the heart, TGF-beta signaling pathway, Wnt signaling pathway, Signal transduction, Signaling events mediated by HDAC class II |
Experiment | Gleason Grade 4 in Gleason Score 7 |
Type of Biomarker | Prognostic |
Cohort | 124 patients, were chosen GS6 (n=41), large volume GS6 (n=26), GS7 (n=28), and GS8 and higher (n=29). |
Senstivity | NA |
Specificity | NA |
AUC | 0.72 (95% CI: 0.59-0.84) |
Accuracy | NA |
Level Of Significance | p<0.01 |
Method Used | fluorescence in situ hybridization (FISH) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |